Previous 10 | Next 10 |
CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that the U.S. Food and...
Gainers : Foresight Autonomous (NASDAQ: FRSX ) +65% . Highpower International (NASDAQ: HPJ ) +39% . Avid Bioservices (NASDAQ: CDMO ) +32% . Phunware (NASDAQ: PHUN ) +30% . Xenetic Biosciences (NASDAQ: XBIO ) +27% . Motorcar Parts of America (NASDAQ: MPAA ) +25% . Unum Therapeutics (N...
– Matthew Osborne Appointed as Chief Financial Officer – – Jessica Sachs Promoted to Chief Medical Officer – – Mert Aktar Appointed as Head of Business and Corporate Development – CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Unum Ther...
Unum Therapeutics Inc. (UMRX) Q1 2019 Results Earnings Conference Call May 13, 2019, 08:00 AM ET Company Participants Stephanie Ascher - Investor Relations Chuck Wilson - Chief Executive Officer John Green - Vice President of Finance Michael Vasconcelles - Chief Medical Officer...
Unum Therapeutics (NASDAQ: UMRX ): Q1 GAAP EPS of -$0.39 misses by $0.04 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation Studies with Data Expected from All Four Ongoing Trials in Second Half of 2019 - - Advancing and Expanding BOXR Pipeline Focused on Solid Tumor Cancers Throu...
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer using its novel T cell technology platforms, today announced that the company will host...
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson, ...
Unum Therapeutics Inc. (UMRX) Q4 2018 Results Earnings Conference Call March 28, 2019, 08:00 AM ET Company Participants Stephanie Ascher - Investor Relations Chuck Wilson - Chief Executive Officer John Green - Vice President of Finance Michael Vasconcelles - Chief Medical Offic...
Unum Therapeutics (NASDAQ: UMRX ): Q4 GAAP EPS of -$0.29 beats by $0.05 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...